ClinicalTrials.gg
CompletedNCT06299098COURAGEUpdated Nov 12, 2026

A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation

A Phase 2 interventional study of Trevogrumab-Part A and Trevogrumab-Part B and Part C in Obesity, sponsored by Regeneron Pharmaceuticals. Completed at 60 sites in 2 countries. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment

Updated Nov 12, 2026Now CompletedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
1,005
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This study is researching experimental drugs called trevogrumab and garetosmab (called "study drugs") in combination with another drug, semaglutide (Wegovy®). This study will be done in 3 parts, Part A, Part B, and Part C where different study drugs will be tested.

Part A of the study is focused on healthy participants. Part B and C of the study is focused on participants with obesity.

The aim of Part A of the study is to see how safe and tolerable the study drug is in healthy participants. The aim of Part B and Part C of the study is to see how safe and effective the study drug is when combined with Wegovy.

Parts A, B, and C of the study are looking at several other research questions, including:

  • What side effects may happen from taking the study drug
  • How much study drug is in the blood at different times
  • Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
Read the detailed description

Part A Healthy Volunteers

Part B and Part C (starts after treatment for Part A has completed) Participants with Obesity

02

Conditions studied

  • Obesity

Browse trials for

Keywords

  • Obesity without diabetes
  • Quality of weight loss
  • Fat mass loss
  • Lean mass loss
03

In context

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

This study's enrollment of 1,005 is above the median of 67 across 9,016 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.

Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria

Part A

  1. Male or female participants age ≥18 to ≤55 years of age at the time of screening
  2. ≥18 and ≤32 kg/m2, at the screening visit

    Part B and Part C

  3. Male or female participants ≥18 to ≤80 years of age at the time of screening
  4. BMI ≥30 kg/m2, at the screening visit
  5. History of 1 or more self-reported unsuccessful dietary attempts to lose weight

Key Exclusion Criteria

  1. History of diabetes (Type 2 or Type 1). History of gestational diabetes is permitted
  2. Previous bariatric surgery or planned bariatric surgery
  3. History of hypertrophic cardiomyopathy
  4. Abnormal (ECG) findings at screening that meet Cornell voltage criteria for left ventricular hypertrophy
  5. Any in the past 5 years prior to screening (except for nonmelanoma skin cancer that has been resected with no evidence of disease for 3 years prior to screening)
  6. History of poorly controlled hypertension, as defined in the protocol
  7. Have a history of any other condition (such as known drug abuse, alcohol abuse, diagnosed eating disorder, or a severe mental illness) that, in the opinion of the investigator, may preclude the participant from following and completing the protocol
  8. Have history of use of marijuana/tetrahydrocannabinol (THC) within 90 days prior to Visit 1 of enrollment and are unwilling to abstain from marijuana/THC use during the trial
  9. Has a history of any neuromuscular disorder (eg, multiple sclerosis, myasthenia gravis, myopathy, peripheral neuropathy, etc)

Note: Other protocol-defined Inclusion/ Exclusion Criteria apply

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,005 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Part A Randomized 1:1

    Drug: Matching Placebo-Part A

  • Experimental
    Trevogrumab

    Part A Randomized 1:1

    Drug: Trevogrumab-Part A

  • Experimental
    Arm A0

    Part B Semaglutide (sema) and subcutaneous (SC) placebo and intravenous (IV) placebo followed by SC placebo Randomized 1:1:1:1:1:1:1:1

    Drug: Semaglutide · Drug: Matching Placebo-Trevogrumab · Drug: Matching Placebo-Garetosmab

  • Experimental
    Arm A1

    Part B Sema and SC placebo and IV placebo followed by high dose trevogrumab (trevo) Randomized 1:1:1:1:1:1:1:1

    Drug: Trevogrumab-Part B and Part C · Drug: Semaglutide · Drug: Matching Placebo-Trevogrumab · Drug: Matching Placebo-Garetosmab

  • Experimental
    Arm B0

    Part B Sema, moderate-high dose trevo, and IV placebo followed by SC placebo Randomized 1:1:1:1:1:1:1:1

    Drug: Trevogrumab-Part B and Part C · Drug: Semaglutide · Drug: Matching Placebo-Trevogrumab · Drug: Matching Placebo-Garetosmab

  • Experimental
    Arm B1

    Part B Sema, moderate-high dose trevo, and IV placebo followed by high dose trevo Randomized 1:1:1:1:1:1:1:1

    Drug: Trevogrumab-Part B and Part C · Drug: Semaglutide · Drug: Matching Placebo-Garetosmab

  • Experimental
    Arm C0

    Part B Sema, high dose trevo, and IV placebo followed by SC placebo Randomized 1:1:1:1:1:1:1:1

    Drug: Trevogrumab-Part B and Part C · Drug: Semaglutide · Drug: Matching Placebo-Trevogrumab · Drug: Matching Placebo-Garetosmab

  • Experimental
    Arm C1

    Part B Sema, high dose trevo, and IV placebo followed by high dose trevo Randomized 1:1:1:1:1:1:1:1

    Drug: Trevogrumab-Part B and Part C · Drug: Semaglutide · Drug: Matching Placebo-Garetosmab

  • Experimental
    Arm D0

    Part B Sema, high dose trevo, and garetosmab (gareto) followed by SC placebo Randomized 1:1:1:1:1:1:1:1

    Drug: Trevogrumab-Part B and Part C · Drug: Garetosmab · Drug: Semaglutide · Drug: Matching Placebo-Trevogrumab

  • Experimental
    Arm D1

    Part B Sema, high dose trevo, and gareto followed by high dose trevo Randomized 1:1:1:1:1:1:1:1

    Drug: Trevogrumab-Part B and Part C · Drug: Garetosmab · Drug: Semaglutide

  • Experimental
    Arm 1

    Part C Sema and SC placebo Randomized 1:2:2

    Drug: Semaglutide · Drug: Matching Placebo-Trevogrumab

  • Experimental
    Arm 2

    Part C Sema and SC low dose trevo Randomized 1:2:2

    Drug: Trevogrumab-Part B and Part C · Drug: Semaglutide · Drug: Matching Placebo-Trevogrumab

  • Experimental
    Arm 3

    Part C Sema and SC moderate dose trevo Randomized 1:2:2

    Drug: Trevogrumab-Part B and Part C · Drug: Semaglutide

Interventions

  • Administered IV or SC in Part A

    Also known as: REGN1033, GDF8

  • DrugTrevogrumab-Part B and Part C

    Drug page: Trevogrumab

    Administered SC in Part B, Part C

    Also known as: REGN1033, GDF8

  • Administered IV in Part B

    Also known as: REGN2477, Activin A

  • Administered SC in Part B and Part C

    Also known as: Wegovy®

  • DrugMatching Placebo-Part A

    Administered IV or SC in Part A

  • DrugMatching Placebo-Trevogrumab

    Administered SC in Part B and Part C

  • DrugMatching Placebo-Garetosmab

    Administered IV in Part B

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events (TEAEs)

    Part A

    Time frame: Baseline to week 7

  2. Severity of TEAEs

    Part A

    Time frame: Baseline to week 7

  3. Percent change in total fat mass

    Part B

    Time frame: Baseline to week 26

  4. Percent change in total lean mass

    Part B

    Time frame: Baseline to week 26

  5. Percent change in body weight

    Part B

    Time frame: Baseline to week 26

  6. Percent change in total fat mass

    Part C

    Time frame: Baseline to week 52

  7. Percent change in total lean mass

    Part C

    Time frame: Baseline to week 52

  8. Percent change in body weight

    Part C

    Time frame: Baseline to week 52

Secondary outcomes

  1. Concentrations of trevogrumab in serum over time

    Part A, Part B, and Part C

    Time frame: Up to 75 weeks

  2. Percent change in total fat mass

    Part B

    Time frame: Baseline to week 52

  3. Percent change in total lean mass

    Part B

    Time frame: Baseline to week 52

  4. Percent change in body weight

    Part B

    Time frame: Baseline to week 52

  5. Change in waist circumference (cm)

    Part B and Part C

    Time frame: Baseline to week 26

  6. Change in waist circumference (cm)

    Part C

    Time frame: Baseline to week 52

  7. Percent change in fasting serum triglycerides

    Part B

    Time frame: Baseline to week 26

  8. Percent change in total cholesterol

    Part B

    Time frame: Baseline to week 26

  9. Percent change in Apolipoprotein B (Apo B)

    Part B

    Time frame: Baseline to week 26

  10. Percent change in Low-Density Lipoprotein Cholesterol (LDL-C)

    Part B

    Time frame: Baseline to week 26

  11. Concentrations of garetosmab in serum over time

    Part B

    Time frame: Up to 75 weeks

  12. Incidence of anti-drug antibodies (ADA) to trevogrumab after repeated doses over time

    Part B and Part C

    Time frame: Up to 75 weeks

  13. Magnitude of ADAs to trevogrumab over time

    Part B and Part C

    Time frame: Up to 75 weeks

  14. Incidence of ADAs to garetosmab after repeated doses over time

    Part B

    Time frame: Up to 75 weeks

  15. Magnitude of ADAs to garetosmab over time

    Part B

    Time frame: Up to 75 weeks

  16. Incidence of TEAEs

    Part B and Part C

    Time frame: Up to 75 weeks

  17. Severity of TEAEs

    Part B and Part C

    Time frame: Up to 75 weeks

  18. Percent change in total fat mass

    Part C

    Time frame: Baseline to week 26

  19. Percent change in total lean mass

    Part C

    Time frame: Baseline to week 26

  20. Percent change in body weight

    Part C

    Time frame: Baseline to week 26

  21. Concentration of total Growth Differentiation Factor (GDF) 8 in serum over time

    Part C

    Time frame: Up to 75 weeks

07

Study locations

60 sites
08

References and documents

Publications

  • Mosenzon O, Rosenstock J, Raya JG, Grimsby JS, Calle RA, Cannon K, Haggag AZ, Bays H, Sarkar N, Templeton A, Fanous M, Lighter J, Vavere A, Yancopoulos GD, Hirshberg B; COURAGE Trial Investigators. Trevogrumab (anti-GDF8) with or without garetosmab (anti-activin A) for prevention of muscle loss during semaglutide-induced weight reduction in people with obesity (COURAGE): a two-part, phase 2, double-blind, placebo-controlled, randomised trial. Lancet. 2026 Nov 11:S0140-6736(26)01953-7. doi: 10.1016/S0140-6736(26)01953-7. Online ahead of print. PubMed 43014326 ↗

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy.

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2024 to primary completion in Jun 2026, 27 months.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 27 months is above that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2024
First posted
Mar 7, 2024
StartActual
Mar 13, 2024
Primary completionActual
Jun 16, 2026
CompletionActual
Oct 21, 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Active, not recruiting→Completed
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06299098
Responsible party
Sponsor
First posted
Mar 7, 2024
Start date
Mar 13, 2024
Primary completion
Jun 16, 2026
Completion
Oct 21, 2026
Last update
Nov 12, 2026

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Trevogrumab · Garetosmab

Start the discussion